This study firstly demonstrated that Atr III could alleviate sepsis-mediated lunginjury via inhibition of FoxO1 and VNN1 protein, and the mechanism might be relatedto down-regulation of pro-inflammatory cytokines and protection of lung function.Atr III can be developed as an effective and safe agent for treating sepsis-inducedlung injury in the future. Here, VNN1 is linked to Sepsis.